Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Ann Med ; 56(1): 2336989, 2024 Dec.
Article in English | MEDLINE | ID: mdl-38738374

ABSTRACT

As the world's population of adults greater than 60 years old continues to increase, it is important to manage nail disorders that may impact their daily lives. Nail disorders may have significant impact on quality of life due to decreased functionality, extreme pain, or social embarrassment. In this review, we discuss nail disorders affecting older patients, including physiologic, traumatic, drug-induced, infectious, environmental, inflammatory, and neoplastic conditions. Diagnosis of these conditions involves a detailed history, physical examination of all 20 nails, and depending on the condition, a nail clipping or biopsy and/or diagnostic imaging. Nails grow even more slowly in older adults compared to younger individuals, and therefore it is important for accurate diagnosis, and avoidance of inappropriate management and delay of treatment. Increased awareness of nail pathologies may help recognition and management of nail conditions in older adults.


Nail disorders are common amongst older adults and may cause decreased functionality, pain, psychosocial problems and impact quality of life.Many nail conditions, both physiologic or pathologic, may have similar presentation in older adults. Confirmation testing is important to avoid inappropriate or delayed treatment.The increased frequency of comorbidities, drug interactions, polypharmacy, and mental or physical limitations with aging must be considered when managing care of older patients with nail disorders.


Subject(s)
Nail Diseases , Nails , Humans , Nail Diseases/diagnosis , Nail Diseases/therapy , Nail Diseases/etiology , Aged , Nails/pathology , Quality of Life , Middle Aged , Aged, 80 and over
3.
Arch Dermatol Res ; 316(1): 51, 2023 Dec 18.
Article in English | MEDLINE | ID: mdl-38108883

ABSTRACT

INTRODUCTION: Phototherapy and photodynamic therapy (PDT) are ultraviolet light (UV) based therapies for patients with skin diseases, and are sometimes associated with potential adverse events (AE)s, including erythema, pain, pruritus, burns, and photoaging. METHODS: We investigated UV phototherapy and PDT safety using the United States (US) Food and Drug Administration's (FDA)'s Manufacturer and User Facility Device Experience (MAUDE) database. The MAUDE database, including medical device reports (MDR)s informed by voluntary and obligatory reporters since 1991, was searched for AEs associated with UV phototherapy and PDT 1/1/91-3/1/23. RESULTS: There were 59 UV phototherapy and 33 PDT related MDRs. Burns were the most common AE type for both phototherapy and PDT. The majority of phototherapy AEs occurred during 2021 (52.3%), and were significantly more likely to occur at home than in the clinic. Overall, 76.1% of MDRs associated with home light boxes were prescribed by online retailers, most of the MDRs (59.3%) mentioned that it is prohibited to sell phototherapy devices not prescribed by physicians, and only 8.5% noted poorly written home light box instructions. DISCUSSION: The COVID-19 pandemic prohibited in-person light treatments, and social distancing requirements may have resulted in increased frequency of home-based light treatments. Hence, while at home treatment may be easier and more accessible, in-office physician supervised UV treatments are associated with less frequent AEs. Moreover, some phototherapy MDRs reported poorly written instructions accompanying the home light box, and some PDT MDRs documented patients receiving inadequate education regarding the procedure. With the rise of at-home treatment options and the ease of obtaining devices on the internet, it is physicians' duty to advise patients against self-treating with home light boxes without prescribed treatment regimens and educate patients that are considering home phototherapy to ensure safer patient experiences.


Subject(s)
Burns , Photochemotherapy , Humans , Pandemics , Retrospective Studies , Phototherapy , Photochemotherapy/adverse effects
4.
Cutis ; 112(4): 203-204, 2023 Oct.
Article in English | MEDLINE | ID: mdl-37988297

ABSTRACT

Pain and anxiety are common in patients undergoing nail surgery, and injection of local anesthetic is the most uncomfortable part of the procedure. Using a portable massager on the ipsilateral limb during nail injection can reduce pain and decrease patient anxiety. It is a simple and safe way to improve the patient experience during nail surgery.


Subject(s)
Hand , Pain , Humans , Pain/etiology , Pain/prevention & control , Anesthesia, Local/methods , Anesthetics, Local , Anxiety/etiology , Anxiety/prevention & control
5.
Skin Appendage Disord ; 9(5): 333-341, 2023 Oct.
Article in English | MEDLINE | ID: mdl-37900771

ABSTRACT

Introduction: Onychomycosis represents half of nail disorders seen in clinical practice. Despite its high prevalence, a bibliometric analysis has not been performed. We aimed to identify the top 100 highly cited onychomycosis publications over the last 50 years to better understand research trends. Methods: SCOPUS was searched for onychomycosis publications, using "onychomycosis" and "nail fungus" 1/1/1972-12/31/22 on 3/25/23. Top 100 highly cited publications were recorded and ranked by total citation count. Results: Total citation count was 13,456, with the top 10 articles with highest citation count/year having average 28.7 citations/year. Most articles were published in high IF journals. From 1982 to 2011 (no treatment articles - 1972-1981), there was an 8.6% increase in articles discussing treatment. Overall, 42% of first authors were female. Conclusion: We found an overall increase in articles discussing onychomycosis therapies over time, with the majority published in high IF journals. We also found a relatively greater percentage of female first authors compared to studies on other dermatologic topics. While total citation count remains a widely used metric of impact in bibliometric studies, average citation count/year may be a better measure of impact and should be considered in future studies.

9.
J Fungi (Basel) ; 9(7)2023 Jun 29.
Article in English | MEDLINE | ID: mdl-37504701

ABSTRACT

Introda significant: Onychomycosis is the most common nail disorder seen in clinical practice, and it may have significant impact on patient quality of life. Understanding risk factors for onychomycosis may help to devise screening and treatment guidelines for populations that are more susceptible to this infection. Using a national database, we aimed to explore associations between onychomycosis and age, sex, and underlying medical conditions, as well as to examine current onychomycosis treatment trends. Materials and Methods: We performed a nested, matched, case-control study of patients in the All of Us database aged ≥ 18 years (6 May 2018-1 January 2022). Onychomycosis cases were identified using International Classification of Diseases (ICD) and Systematized Nomenclature of Medicine (SNOMED) diagnostic codes (ICD-9 110.1, ICD-10 B35.1, SNOMED 414941008). Demographic information (i.e., age, sex, and race), treatments, and co-diagnoses for onychomycosis patients and case-controls were recorded. Wald's test applied to multivariate logistic regression was used to calculate odds ratios and p-values between onychomycosis and co-diagnoses. Additionally, 95% confidence intervals were calculated with a proportion test. Results: We included 15,760 onychomycosis patients and 47,280 matched controls. The mean age of onychomycosis patients was 64.9 years, with 54.2% female, 52.8% Non-Hispanic White, 23.0% Black, 17.8% Hispanic, and 6.3% other, which was similar to controls. Patients with onychomycosis vs. controls were more likely to have a co-diagnosis of obesity (46.4%, OR 2.59 [2.49-2.69]), tinea pedis (21.5%, OR 10.9 [10.1-11.6]), peripheral vascular disease (PVD) (14.4%, OR 3.04 [2.86-3.24]), venous insufficiency (13.4%, OR 3.38 [3.15-3.59]), venous varices (5.6%, OR 2.71 [2.47-2.97]), diabetes mellitus (5.6%, OR 3.28 [2.98-3.61]), and human immunodeficiency virus (HIV) (3.5%, OR 1.8 [1.61-2.00]) (p < 0.05, all). The most frequently prescribed oral and topical medications were terbinafine (20.9%) and ciclopirox (12.4%), respectively. The most common therapeutic procedure performed was debridement (19.3%). Over the study period, ciclopirox prescriptions (Spearman correlation 0.182, p = 0.0361) and fluconazole prescriptions increased (Spearman correlation 0.665, p = 2.44 × 10-4), and griseofulvin (Spearman correlation -0.557, p = 0.0131) and itraconazole prescriptions decreased (Spearman correlation -0.681, p = 3.32 × 10-6). Conclusions: Our study demonstrated that age, obesity, tinea pedis, PVD, venous insufficiency, diabetes mellitus, and HIV were significant risk factors for onychomycosis. In addition, the most frequent oral and topical onychomycosis medications prescribed were terbinafine and ciclopirox, likely reflective of efficacy and cost considerations. Identifying and managing these risk factors is essential to preventing onychomycosis' primary infections and recurrences and improving treatment efficacy.

SELECTION OF CITATIONS
SEARCH DETAIL
...